Deciphex Secures €3.9m Funding to Boost Digital Pathology and AI Services

The company is seeing a ten-fold increase in demand quarterly and this strategic investment will allow them to grow their capacity, increase headcount, further improve services and expand to new markets Deciphex, a leading provider of pathology software and services, announced today a further €3.9m in funding bringing its full Series B round tally to €14.4m. The additional investment, led by Seroba Life Sciences and existing Deciphex investors, will allow Deciphex to continue developing its innovative products and services, to expand its presence in the UK, Canada, the Middle East and the US, and to strengthen its position as a leader in the field of digital pathology and AI. Jennifer McMahon, a partner with Seroba, will join the Board of Deciphex. With people living longer and populations increasing, the need for high-quality, reliable Diagnosis has increased exponentially.  Global pathology capacity cannot increase substantially enough to keep pace with demand. Chronic issues in Pathology such as burgeoning patient wait times, recruitment, demand for expertise and diagnostic complexity has necessitated innovative solutions for optimal patient care. The recent spike in clinical and non-clinical digital pathology use combats the manual and subjective aspects of the previous standard of care while giving Pathologists and laboratories the tools they need to keep up with the expanding cancer burden. Pathology is the hidden engine room of medical treatment and touches 95% of...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Health IT Company Healthcare IT Chronic Issues Deciphex Diagnexia digital pathology Digital Pathology Funding Donal O’Shea Health IT Funding Health IT Fundings Health IT Investment Jennifer McMahon Optimal Patient Care Patholyt Source Type: blogs